OncoMatch/Clinical Trials/NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Is NCT05006716 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BGB-16673 for b-cell malignancy.
Treatment: BGB-16673 — Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance)
Must have received: BTK inhibitor — expansion cohort (MCL, CLL/SLL)
participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy; CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2)
Must have received: Bcl-2 inhibitor — expansion cohort (CLL/SLL)
CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham Hospital · Birmingham, Alabama
- Mayo Clinic Phoenix · Phoenix, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- University of Arizona Cancer Center · Tucson, Arizona
- University of California San Diego (Ucsd) Moores Cancer Center · La Jolla, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify